首页 > 市场调查报告书 > 製药

消化器

慢性肝病治疗药物市场：依治疗类型、疾病类型、分布类型、地区：市场规模、份额、展望、机会分析，2023-2030

市场调查报告书

商品编码

1350246

慢性肝病治疗药物市场：依治疗类型、疾病类型、分布类型、地区：市场规模、份额、展望、机会分析，2023-2030

Chronic Liver Diseases Therapeutics Market, By Treatment Type, By Disease Type, By Distribution type, And By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年08月18日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球慢性肝病药物市场规模为152亿美元，预测期内（2023-2030年）复合年增长率为10.9%。

报告范围		报告详情
基准年	2022年	2023年市场规模	美国：152亿美元
之前的数据	2018年至2021年	预测期	2023-2030
预测 2023-2030 年复合年增长率：	10.90%	2030年价值预测	美国：313亿美元

肝臟是体内最大的固体器官，负责产生用于消化食物的胆汁、将食物转化为能量以及体内足够水平的化学物质，以储存所有细胞和生物活动所需的营养。的角色，包括维持因此，肝功能不正常会导致甲型肝炎、B型肝炎、C型肝炎、原发性肝硬化、肿瘤等多种严重疾病。肝功能障碍的主要原因包括肥胖、过度饮酒和遗传性疾病。肝病的治疗包括抗病毒药物、免疫抑制剂、疫苗、免疫球蛋白、皮质类固醇、标靶治疗和化疗。此外，慢性肝病还包括肝炎、自体免疫疾病、非酒精性脂肪肝（NAFLD）、癌症和遗传性疾病。

市场动态

慢性肝病人口不断增加，研发活动不断增加，以开发治疗肝病的新技术，以及市场上运营的主要公司采取合併、收购、联盟和合作等无机增长策略。预计将在预测期内推动全球慢性肝病治疗药物市场成长的主要因素。例如，2022 年 12 月，专注于开髮用于治疗肥胖和肝病的新型□疗法的临床阶段生物製药公司 Altimmune, Inc. 宣布，非酒精性脂肪肝疾病宣布了 24 项研究的积极顶线结果。Pemvidutide在该疾病中的为期一周（延长12 週）的试验，证明了其显着降低肝臟脂肪含量和肝炎的潜力。此外，2022 年 1 月，Madrigal Pharmaceuticals, Inc. 是一家临床阶段的生物製药公司，致力于脂肪肝疾病的新疗法。我们的主要临床候选药物 resmetilom 宣布了来自安慰剂对照、双盲版本的 resmetilom 3 期 MAESTRO-NAFLD（非酒精性脂肪肝病）安全性研究的积极顶线临床数据。

本次测试的主要特点

该报告对全球慢性肝病治疗市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和复合年增长率（CAGR）。
它还阐明了各个细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景、主要参与者采取的竞争策略等的重要见解。
根据公司亮点、产品组合、主要亮点、绩效和策略等参数对全球慢性肝病药物市场的主要参与者进行了分析。
研究涵盖的主要公司包括Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.。
全球慢性肝病治疗药物市场报告针对该行业的各个利益相关者，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
透过用于分析全球慢性肝病治疗药物市场的各种策略矩阵，将有助于利害关係人做出决策。

公司简介
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

第10章

参考
调查方法

简介目录

Product Code: CMI4047

The global chronic liver diseases therapeutics market is estimated to be valued at US$ 15.2 billion in 2023 and is expected to exhibit a CAGR of 10.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 15.2 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	10.90%	2030 Value Projection:	US$ 31.3 Bn

Chronic Liver Diseases Therapeutics Market - IMG1

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

This report provides an in-depth analysis of the global chronic liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
- Antiviral drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Liver Diseases Therapeutics, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution type
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Chronic Liver Diseases Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Non-alcoholic Fatty Liver Disease (NAFLD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Chronic Liver Diseases Therapeutics Market, By Regions, 2018-2030 (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Astellas Pharma Inc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

慢性肝病治疗药物市场：依治疗类型、疾病类型、分布类型、地区：市场规模、份额、展望、机会分析，2023-2030